Companies in #Endocrine and Metabolic Disease
Found 1 company operating in this sector.
Amylyx Pharmaceuticals is a clinical-stage pharmaceutical company developing therapies for neurodegenerative diseases, endocrine disorders, and metabolic conditions. Its original product AMX0035 (Relyvrio) was withdrawn from the U.S. and Canadian markets after the Phase 3 PHOENIX trial failed to show benefit in ALS. The company is now advancing AMX0035 in post-bariatric hypoglycemia (Phase 3 LUMA trial) and exploring additional endocrine and neurology indications, with co-CEOs Justin Klee and Josh Cohen framing Amylyx as a multi-asset neuroscience and metabolic player.